In recent years, the concept of "standardized management of care" has garnered substantial attention worldwide. Drafting of disease management guidelines that specify appropriate diagnosis and treatment based on scientific evidence and collaborations between medical professionals involved in the treatment of a given condition is the key to standardized management of care (1, 2) . The purpose of evidence-based clinical practice guidelines (CPGs) is to "translate the best current research evidence into clinical practice and obtain new evidence in the course of influencing practitioners' attitude and clinical decision-making".
CPGs have been used for the standardized management of hepatocellular carcinoma (HCC) in many countries worldwide, as exemplified by guidelines implemented in Japan and South Korea. China accounts for 55% of HCC cases worldwide (3) . However, such evidencebased CPGs have not yet to be drafted, hampering the standardized management of HCC in China.
In Japan, HCC management has achieved remarkable results that are attributed to a combination of quantitative and qualitative evaluations incorporated in the Japanese guidelines (4) . Since the first Japanese evidence-based CPGs for HCC (J-HCC Guidelines) were published in 2005, the CPGs have been included a process of systematic evaluation in accordance with evidence-based medicine (EBM) (5, 6) . Updated J-HCC Guidelines incorporating new evidence were published in 2009 (7) , and the third version of J-HCC Guidelines Commentary promote the standardized management of HCC in Japan.
To draft the 2013 version of J-HCC Guidelines, literature consisting of 6,750 papers was systematically reviewed to obtain the best current evidence. After a second round of review, 596 articles were ultimately selected to form 57 pairs of clinical questions and recommendations with different levels of evidence to guide clinical decision-making. A multi-disciplinary expert panel consisting of surgeons, internists, radiologists, statisticians, and health care economists supervised their individual specialties. The guidelines cover aspects including prevention, diagnosis and surveillance, surgery, local treatment, transcatheter arterial chemoembolization (TACE), chemotherapy, radiotherapy, follow-up, prevention and treatment of recurrence. The guidelines also take the Japanese health insurance system into account to make surveillance, diagnosis, and treatment of HCC feasible. In order to adequately reflect disparate views, an internal evaluation and an external evaluation were conducted prior to publication and then the draft guidelines were modified. Moreover, plans are to revise the current guideline yet again. An updated vision of the J-HCC Guidelines will be published in the coming 3-4 years and incorporate new evidence (8) .
In China, HCC is the second most common cancer in urban areas and the most common in rural areas; it ranks as the second leading cause of cancerrelated deaths in males, with a total mortality rate of 26.26/100,000 (9, 10) . Over the past decades, the Government has devised a series of directives on the management of HCC in order to reduce incidence and mortality and to improve healthcare quality overall for patients. For instance, ''Treatment Standards for Common Malignant Tumors in China (Vol. 2, Hepatocellular Carcinoma)'' was published in1989, ''Guiding Principles for Clinical Research on Treatment of Hepatocellular Carcinoma Involving New Drugs/ Traditional Chinese Medicines'' was published in 1990, and "Choices for Hepatocellular Carcinoma Treatment Therapies'' was published in 2000. However, none of these directives was based on a systematic review and evaluation of the literature. Cognizant of the concept of "standardized management of care", the Chinese Guidelines on HCC -Expert Consensus on the Treatment Standards for Hepatic Carcinomawas published in 2009 (11) . However, the guidelines were based on expert consensus, so they provided recommendations regarding the management of HCC based on the experience of those experts instead of recommendations supported by data provided by a systematic review and evaluation of the literature (12).
Fortunately, a high level of liver surgery is currently practiced at leading medical facilities in China (13) . A team in Beijing led by Dr. Jiahong Dong put forth the novel concept of "precision surgery". This concept represents a new surgical paradigm that includes preoperative evaluation, clinical decision-making, surgical planning, surgical technique, and perioperative management, and this concept should encourage the standardized management of HCC in China (14) . "Precision surgery" involves certainty-based practices to ensure the best result for each patient with multiobjective optimization of therapeutic effectiveness, surgical safety, and minimal invasiveness. However, this paradigm is based on the clinical experience of surgeons who perform over 700 hepatic resections each year. Recommendations supported by data are still urgently needed to guide clinical decision-making.
In conclusion, the practice of systematic evidencebased CPGs in Japan provides a good example of standardized management of HCC. Such guidelines need to be promptly drafted in China through systematic review and evaluation of the literature by a multi-disciplinary expert panel in order to provide recommendations supported by data to guide clinical decision-making.
